NASDAQ · Biotechnology

Eledon Pharmaceuticals, Inc. (ELDN) Stock

$2.48 +2.48% NASDAQ: ELDN Healthcare

Valuation

MetricValue
Price$2.48
Market Cap$191.43M
P/E Ratio-2.53
P/B Ratio3.95
P/S Ratio0.00
EPS (TTM)$-0.80
52-Week High$4.60
52-Week Low$1.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-136.45%
ROA-78.16%
ROCE-74.02%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio7.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-37.0M$-88.0M$-43.0M$-71.0M$-83.0M
Net Profit$-35.0M$-88.0M$-117.0M$-36.0M$-46.0M
EPS$-2.33$-6.16$-4.73$-0.75$-0.56
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$171.0M$93.0M$89.0M$177.0M$169.0M
Total Liabilities$7.0M$9.0M$82.0M$59.0M$88.0M
Cash$85.0M$56.0M$5.0M$21.0M$23.0M
Borrowings$1.0M$1.0M$0$1.0M$1.0M

Latest News

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board GlobeNewswire · Jul 8, 2026 NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes GlobeNewswire · Jul 1, 2026 Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial MT Newswires · Jun 25, 2026 Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial Business Wire · Jun 25, 2026 Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-29.0M$-28.0M$-40.0M$-47.0M$-62.0M
Investing Cash Flow$0$0$-45.0M$-70.0M$11.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-29.0M$-28.0M$-52.0M$16.0M$2.0M
Free Cash Flow$-29.0M$-28.0M$-40.0M$-47.0M$-62.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-2.31
FCF Yield-38.20%
Quick Ratio7.90
Interest Coverage0.00
Return 1Y-1.84%
Return 3Y187.69%
Return 5Y-43.28%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABEOAbeona Therapeutics Inc. $4.94 -0.40% -4.43 $281.56M 0.00%
ACHVAchieve Life Sciences, Inc. $7.41 +3.06% -4.67 $760.70M 0.00%
ALLOAllogene Therapeutics, Inc. $1.46 +4.29% -2.24 $503.93M 0.00%
AVIRAtea Pharmaceuticals, Inc. $5.15 -0.10% -2.47 $412.14M 0.00%
EDITEditas Medicine, Inc. $2.90 +2.11% -3.50 $445.04M 0.00%

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is led by CEO David-Alexandre C. Gros, employs 31 people, headquartered in US, publicly traded since 2014.

Eledon Pharmaceuticals, Inc. (ELDN) stock trades at $2.48 with a market capitalization of $191.43M. The stock is valued at a price-to-earnings (P/E) ratio of -2.53, price-to-book of 3.95, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.35 and $4.60, and currently trades 46.1% below its 52-week high.

On profitability, Eledon Pharmaceuticals, Inc. generates a return on equity (ROE) of -136.45%, return on capital employed of -74.02%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides